Introduction:
In contrast to many neurological disorders, psychiatric disorders do not manifest observable changes in the brain through a naked-eye examination. However, recent advances in neuroimaging, particularly quantitative structural imaging like voxel-based morphometry, as well as functional neuroimaging methods such as MRI (magnetic resonance imaging), positron emission tomography scan (PET), and single photon emission computed tomography (SPECT), have made it possible to investigate these disorders.
Furthermore, psychiatric neuroimaging has seen significant progress through its integration with genetics, known as "imaging genetics." In these studies, researchers compare neuroimaging results among different genetic variants within a population to identify imaging characteristics that can be measured and potentially serve as biomarkers for therapeutic research. This approach helps establish links between brain structures and specific genes and uncovers the molecular foundations of how different brain regions are organized and function.
What Is the Significance of Neuroimaging?
Neuroimaging in Psychiatric Diagnosis:
1. Neuroimaging can help differentiate psychiatric symptoms from neurological conditions that mimic psychiatric disorders.
2. Psychotic disorders may result from brain lesions, often tumors, in frontal or temporal lobes, which can be detected through neuroimaging.
3. Behavioral syndromes can be caused by seizures originating from tumors or brain lesions.
4. Thalamic or hypothalamic lesions can present with psychotic features or apathy, sometimes mistaken for depression.
5. Neuroimaging is valuable in distinguishing between neurodegenerative disorders and depression, especially in older individuals.
6. Specific patterns in neuroimaging can characterize conditions like Alzheimer's disease, Lewy body disease, and frontotemporal dementia.
7. Negative results in PET or SPECT scans can reduce the likelihood of neurodegenerative disorders, but neuroimaging alone may not provide definitive diagnoses.
Neuroimaging in Psychiatric Disorders:
1. Psychiatric disorders are heterogeneous, making their neurobiological basis complex and variable among individuals.
2. Neuroimaging findings often lack specificity and don't directly connect to a single neurobiological cause.
3. In schizophrenia, structural and functional neuroimaging has revealed volume reductions in specific brain regions and abnormal activation patterns.
4. Major depressive disorder is associated with elevated metabolism and reduced volume in the subgenual region of the medial frontal lobe.
5. Functional MRI patterns can help distinguish depression from other conditions.
6. Genotypic variations may influence the likelihood of developing depression and impact imaging findings.
7. Neuroreceptor PET imaging has identified decreased binding potential of certain receptors in specific brain regions in major depression.
8. Neuroimaging findings are valuable but should be interpreted alongside clinical assessments for accurate psychiatric diagnoses.
What Is the Role of Neuroimaging in Drug Development?
The role of neuroimaging in drug discovery and development:
Neuroimaging in Drug Discovery and Development:
1. Neuroimaging plays a crucial role at various stages of drug development:
-
Characterizing preclinical models.
-
Demonstrating target engagement by new drugs.
-
Proving the concept (PoC) that a drug engaging a specific target results in a meaningful clinical benefit.
2. Neuroimaging in preclinical models helps assess the binding of new compounds to targets like glycine transporter 1, relevant to schizophrenia.
3. Neuroimaging can be a biomarker in therapeutic drug development, assessing a drug's effects on brain structure and function.
4. Biomarkers in drug development can be categorized into three types: type 0 (tracking disease progression), type 1 (effects of intervention without a direct link to clinical outcome), and type 2 (predictive of clinical outcome).
5. Neuroimaging can help establish proof of concept (PoC) for drugs, as seen with D2 receptor occupancy in schizophrenia treatment.
Role of Neuroimaging Modalities in Drug Development:
6. PET and SPECT are valuable neuroimaging techniques for exploring neurotransmitter systems, particularly dopaminergic ones.
7. PET tracers have been used to study presynaptic dopamine synthesis and postsynaptic receptor binding (D1, D5, D2, D3, D4), and newer compounds are employed to study D2, D3, and D4 receptors in various brain regions.
8. SPECT imaging utilizes radioligands to investigate targets like the dopamine transporter (DAT) with compounds such as Ioflupane.
9. High-resolution structural MRI can complement PET and SPECT for anatomical detail.
10. Neuroimaging helps determine critical properties of candidate drugs, including their ability to cross the blood-brain barrier (BBB), target engagement, and pharmacodynamic effects.
11. PET radiolabeling of candidate drugs allows studies on their brain distribution, washout characteristics, and BBB permeability. However, it is challenging and may lead to underestimations.
12. An alternative strategy is to label the target instead of the drug, using existing PET/SPECT tracers to assess target occupancy.
13. Neuroimaging is essential for understanding drug behavior, such as serotonin transporter occupancy in depression treatment.
Why Is Neuroimaging Important in Psychiatric Disorders?
Neuroimaging has played a crucial role in uncovering the brain regions and functions associated with psychiatric disorders, with a focus on functional connectivity (FC) analysis using functional magnetic resonance imaging (fMRI). FC refers to brain regions' synchronized activation and deactivation during specific cognitive functions, often forming networks.
In psychiatric illnesses, including geriatric depression, three significant functional networks have been identified:
1. Executive Control Network (ECN): Comprising the dorsolateral prefrontal cortex, medial frontal cortex, and lateral parietal cortex, the ECN is responsible for complex cognition, particularly executive control.
2. Default Mode Network (DMN): The DMN includes the medial prefrontal cortex, posterior cingulate cortex (PCC), inferior parietal cortex, and hippocampus. It is typically active during internal thoughts and deactivated during complex cognitive tasks.
3. Salience or Emotional Processing Network (SN): The SN involves the right anterior insula and dorsal anterior cingulate cortex (dACC) and plays a role in assessing the significance of stimuli and assigning emotional and motivational value.
Analyzing FC abnormalities between these brain regions or networks helps clarify the clinical symptoms linked to specific neural substrates. It offers insights into potential treatment targets, especially in late-life depression (LLD) and cognitive decline.
In LLD (late-life depression), pronounced symptoms such as executive dysfunction, rumination, apathy, and negativity bias are associated with specific FC patterns:
-
Reduced FC within the ECN is linked to worse executive function and cognitive control over emotions.
-
Increased FC within the DMN and SN correlates with greater depression severity.
-
Patients who achieve depression remission show altered FC patterns within the ECN and DMN, while non-remitters do not.
-
Enhanced positive FC between the ECN and SN is related to worse executive function and apathy in LLD.
Conclusion:
Neuroimaging is playing a growing role in the advancement of psychiatric treatments. It allows clinicians to investigate whether specific drug targets are affected in psychiatric disorders and whether correcting these abnormalities could lead to therapeutic benefits. By using neuroimaging to label either a new drug or its target, we can assess whether the drug can effectively penetrate the blood-brain barrier and bind to its intended target, along with determining the required dosage. Moreover, neuroimaging helps identify individuals who exhibit the expected pharmacological response to the drug, enabling the selection of the most suitable participants for clinical trials likely to benefit from the treatment.
